Melanoma Insights for Professionals

Due to the highly aggressive nature of Merkel cell carcinoma, accurate and timely diagnosis is essential to ensure optimal management. Although our understanding of the biology of the disease has advanced significantly in recent years, a clinical conundrum still exists regarding the ideal therapeutic strategy for each patient. 

In this podcast, our multidisciplinary panel discuss: 

In addition, the panel reviews two case studies to put learnings into practice. 

This podcast is suitable for Medical Oncologists, Surgeons, Dermatologists, GPs, Nurses and other healthcare professionals. 

Please note that this podcast was accurate at the time of recording (March 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. 

SPEAKERS: 

Hear our expert multidisciplinary panel discuss the latest management options for the treatment of squamous cell carcinoma and basal cell carcinoma - the most common forms of non-melanoma skin cancers. They have a wide clinical and pathological presentation, and early detection and treatment is vital to reduce the morbidity and mortality associated with these diseases.

In this podcast, our multidisciplinary panel discuss:

In addition, the panel review two cases to solidify the learnings.

This podcast is suitable for Medical Oncologists, Surgeons, Dermatologists, GPs, Nurses and other healthcare professionals.

Please note that this podcast was accurate at the time of recording (March 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

SPEAKERS:

Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital

Dr Kerwin Shannon - Surgical Oncologist and Head and Neck Surgeon, Melanoma Institute Australia and Chris O’Brien Lifehouse

Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia |Clinical Professor, The University of Sydney

Dr Ines Silva - Medical Oncologist and Researcher, Melanoma Institute Australia | Fellow, Westmead Hospital

The success of immunotherapy and targeted therapy in the treatment of advanced melanoma has led to the same therapies being used in the adjuvant setting to reduce the risk of recurrence. 

In this podcast, A/Prof Matteo Carlino interviews fellow Medical Oncologist A/Prof Alexander Menzies on the evidence for adjuvant therapy to guide clinical decision-making. Understanding the complexities of adjuvant therapy is key to identifying and managing patients suitable for this treatment. Topics covered in this discussion include:

This podcast is suitable for Oncologists, Oncology Nurses and other healthcare professionals. 

Please note that this podcast was accurate at the time of recording (Feb 2021) but may not reflect the rapidly evolving treatment landscape and approvals in Australia. 

SPEAKERS: 

In the rapidly evolving treatment landscape for advanced melanoma, medical oncologists now have a suite of treatments to choose from for their patients. In this engaging podcast, A/Prof Menzies interviews fellow Medical Oncologist A/Prof Carlino on the rationale behind their clinical decision making when it comes to choosing the most appropriate therapy for their patients, including sequencing and combination therapies. They also take a deeper dive into treatment toxicities and how to manage them for targeted and immune therapies. 

This podcast is suitable for Oncologists, Oncology Nurses and other healthcare professionals.

Please note that this podcast was accurate at the time of recording (June 2020) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

Melanoma is one of the most common human malignancies, however we often don't often think of it as a disease that occurs in children. Although exceedingly rare, clinicians do need to be aware of paediatric melanoma and have a high level of suspicion for these lesions as they are often diagnosed late. 

In this podcast, a Surgeon, Dermatologist and Medical Oncologist discuss how melanoma presents in children and adolescents, and how this differs from the adult setting. They also discuss how melanoma should be managed in these patients and discuss two patient case studies. 

This podcast is suitable for Surgeons, Dermatologists, Medical Oncologists, GPs and other healthcare professionals.

SPEAKERS

• A/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia, Westmead and Blacktown Hospitals | Clinical Associate Professor, The University of Sydney
• Dr Gideon Sandler - Consultant Adult and Paediatric Head and Neck Surgeon and Surgical Oncologist, Westmead Hospital and the Children’s Hospital at Westmead Affiliate, Melanoma Institute Australia
• Dr Li-Chuen Wong - Consultant Paediatric and Adult Dermatologist and Head of Dermatology | Children’s Hospital at Westmead

Please note that this podcast was accurate at the time of recording (March 2020) but maynot reflect the rapidly evolving treatment landscape and approvals in Australia.

For more practice-changing education, visit our Melanoma Education Portal. MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE. 

In the last decade, the treatment landscape for melanoma has been transformative for patients with advanced disease. Although managed primarily by medical oncologists, it is important for GPs to be across which treatments are available for their patients as they are often the first point of contact when a patient becomes unwell. 

In this podcast, Medical Oncologist Professor Georgina Long discusses how systemic therapy is used in the treatment of advanced melanoma, and how a GP can identify and manage toxicities in patients being treated with targeted or immunotherapies. 

This podcast is suitable for GPs, Skin Cancer GPs, nurses and other healthcare professionals.

Please note that this podcast was accurate at the time of recording (Oct 2019) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

Thanks to advancements in therapy, we are now seeing large numbers of patients surviving advanced melanoma, and with that comes well-being and psychological challenges that need to be addressed. Clinicians need to be cognisant of their patients' needs beyond the medical side.Dietitian Jane Freeman, Psychologist Michelle Davey and Physiotherapist Carol Morris discuss the role that food, mood and movement has in the holistic approach to treating melanoma patients and survivors, and the role that you - as a clinician - can play.This podcast is suitable for oncologists, GPs, oncology nurses and other healthcare practitioners.

Please note that this podcast was accurate at the time of recording (May 2019) but maynot reflect the rapidly evolving treatment landscape and approvals in Australia. For more practice-changing education, visit our⁠ Melanoma Education Portal. ⁠MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE. 

The management of melanoma patients with brain metastases has changed rapidly in the last five years, and patients now have much-improved survival rates. Brain metastases are no longer a death sentence and many people can have control of their disease with quality life.In this podcast, Medical Oncologist A/Prof Alex Menzies, Neurosurgeon Dr Brindha Shivalingam and Radiation Oncologist Prof Angela Hong discuss the contemporary multidisciplinary management of patients with brain metastases and through examining two case studies, they discern the factors that need to be considered for deciding best practice.This podcast is suitable for medical oncologists, rural oncologists, radiation oncologists, surgeons (including neurosurgeons), and may also be of interest to GPs, oncology nurses and other healthcare practitioners.

Please note that this podcast was accurate at the time of recording (March 2019) but maynot reflect the rapidly evolving treatment landscape and approvals in Australia.

For more practice-changing education, visit our⁠ Melanoma Education Portal. ⁠MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.